Guidance Manual Quality Control Testing of...
Transcript of Guidance Manual Quality Control Testing of...
Guidance Manual-Quality control testing of Streptokinase Page 1 of 42
NIB/EHL/GM/01
Guidance Manual
“Quality Control Testing of Streptokinase”
NATIONAL INSTITUTE OF BIOLOGICALS (Ministry of Health & Family Welfare)
Government of India A-32, SECTOR-62,
NOIDA (Uttar Pradesh) PIN: 201307
Web site: www.nib.gov.in, e-mail: [email protected]
Guidance Manual-Quality control testing of Streptokinase Page 2 of 42
NIB/EHL/GM/01
ABBREVIATIONS USED
AMC Annual maintenance contact
ASO Anti Streptolysin-O
BP British Pharmacopoeia
BSA Bovine Serum Albumin
CDSCO Central Drugs Standards and Control Organization
CoA Certificate of analysis
CPB Citrophosphate Buffer
CRS Certified Reference standard
CSE Control standard endotoxin
DCA Drugs and Cosmetic Act
DCG(I) Drugs Controller General of India
DID Double immune diffusion
EHL Enzymes and Hormones laboratory
EP European Pharmacopoeia
EU Endotoxin unit
FSH Follicle stimulating hormone
FTIR Fourier transform Infrared spectrophotometer
HBsAg Hepatitis B surface antigen
hCG Human Chorionic Gonadotropin
HCV Hepatitis C virus
HIV Human Immuno deficiency virus
HMG Human Menopausal Gonadotropin
HPLC High performance liquid chromatography
HSA Human Serum Albumin
IAEC Institutional Animal Ethics Committee
IEC International electro technical commission
IP Indian Pharmacopoeia
IPC Indian Pharmacopoeia Commission
Guidance Manual-Quality control testing of Streptokinase Page 3 of 42
NIB/EHL/GM/01
IRS International reference standard
ISO International organization for standardization
IU International Unit
LAL Limulus Amoebocyte Lysate
LH Luteinizing hormone
LRW LAL Reagent Water
MVD Maximum valid dilution
NABL National Accreditation Board for Testing and Calibration Laboratories
NCL National control laboratory
NIB National Institute of Biologicals
NIBSC National Institute of Biological Standards and Control
NPC Negative product control
NWC Negative water control
PEG Poly ethylene glycol
PPC Product positive control
PWC Positive water control
QA Quality Assurance
QC Quality Control
RBC Red Blood Cell
RT Room temperature
rDNA Recombinant DNA
SOP Standard Operating Procedure
SR & RDU Sample Receipt and Report Dispatch Unit
TTI Transfusion transmitted infection
USP United States Pharmacopoeia
WRP Working reference preparation
Guidance Manual-Quality control testing of Streptokinase Page 4 of 42
NIB/EHL/GM/01
Contributors:
Dr. J. P. Prasad Scientist Grade II, Laboratory Head [email protected]
Mrs. Sudha V. Gopinath Scientist Grade-III [email protected]
Mr. N. Nanda Gopal Junior Scientist [email protected]
Mr. Subhash Kumar Laboratory Technician [email protected]
Mr. Rajeev Shrivastava Laboratory Assistant [email protected]
Guidance Manual-Quality control testing of Streptokinase Page 5 of 42
NIB/EHL/GM/01
ACKNOWLEDGEMENT
I take this opportunity to express my gratitude to all the scientific staff of Enzymes and
Hormones laboratory Ms. Sudha V. Gopinath, Mr. N. Nanda Gopal and help provided by
Mr. Subhash Kumar and Mr. Rajeev kumar Shrivastava in preparing the “Guidance
Manual on Quality Control testing of Streptokinase”.
I would like to show my greatest appreciation to Dr. Surinder Singh, Director (i/c),
National Institute of Biologicals, who has motivated and encouraged every time, without
his encouragement and guidance this document would not have materialized.
This document has taken a shape with the past experience in establishing the laboratory
and taken a way to get an Accreditation for ISO/IEC 17025. I hope this document will
provide guidance to manufacturers / importers /personnel engaged with Quality Control
testing of Streptokinase in establishing quality system.
The guidance and support received from all the members who contributed was vital for the
success. I am grateful for their constant support and help.
Any suggestion in improving the document is highly appreciable.
I wish all success who has contributed in bringing the guidance document.
Dr. J. P. Prasad
Head,
Enzymes & Hormones Laboratory.
Guidance Manual-Quality control testing of Streptokinase Page 6 of 42
NIB/EHL/GM/01
Table of Contents
S.No Contents Page No
1. Purpose 7
2. Scope 7
3. Introduction to Healthcare and Biotherapeutics 8
4. Introduction to Streptokinase 9
5. Quality control test parameters of Streptokinase 11
6. Sample receiving, transfer & testing plan 12
7. Inter laboratory testing 12
8. Data analysis and preparation of Certificate of Analysis 13-16
9. Infrastructure of the laboratory 16-17
10. Reference standards 17-20
11. Biosafety procedures & biomedical waste disposal 21-23
12. Description of test procedures 23-36
13. Documents required for protocol scrutiny 37
14. Quantity of vials required for evaluation 37
15. Training 37
16. Annexures 38-41
17. References 42
Guidance Manual-Quality control testing of Streptokinase Page 7 of 42
NIB/EHL/GM/01
The National Institute of Biologicals (NIB) is an autonomous institute under Ministry of
Health & Family Welfare, Government of India. The mandate of the Institute is to test
Biological products, both manufactured indigenously and imported as per Pharmacopoeial
specifications, collaborate with Indian Pharmacopoeial Commission in finalizing the
specifications, train personnel in the public and private sectors, prepare National reference
standards, collaborate with other scientific institutions in upgrading technologies and
keeping abreast of scientific advances made in the field of quality assessment of Biological
products. The Institute also provides technical expertise to the Central Drugs Standards
and Control Organization (CDSCO) and participates in regulatory visits to manufacturing
facilities on the request of CDSCO.
Purpose
The purpose of this guidance manual is to assist the manufacturers of Streptokinase
including laboratories in developing a quality assurance (QA) program and quality control
(QC). This will also guide in establishing tests related to biophysicochemical and safety
test parameters given in this manual are intended to help the manufacturers / labs to
strengthen the quality of Streptokinase.
Scope:
This document will provide a guidance to manufacturers / personnel working in a quality
control testing Laboratory of Biotherapeutics like enzymes (Streptokinase) to put the
quality system in place while establish a testing laboratory. This gives a systematic
approach to establish as per the regulation, data standards and to maintain good
laboratory practices that will provide reliable and reproducible results. The approach will
ensure the quality of the test procedures carried out and the information which is
generated to provide robust evidence.
Guidance Manual-Quality control testing of Streptokinase Page 8 of 42
NIB/EHL/GM/01
Indian Health care & biotherapeutics:
India‟s growing population, demand for quality drug products and innovative drugs to
combat diseases are leading to increased demand for biotechnology drugs and products.
New types of diseases and demand for improved drugs are also leading to greater
research and development (R&D) activities. A category of such biopharmaceutical
promising to combat diseases and disorders includes therapeutic enzymes.
The concept of the therapeutic enzyme has been around for at least 40 years. In 1987, the
first recombinant enzyme drug, Activase®. (Alteplase; recombinant human tissue
plasminogen activator), was approved by the Food and Drug Administration (FDA). This
„clot-buster‟ enzyme is used for the treatment of heart attacks caused by the blockage of a
coronary artery by a clot formation. This was the second recombinant protein drug to be
marketed.
Biotechnology innovations have made significant contributions in the field of health care
with more than 200 biologic medicines and vaccines benefiting millions of patients
worldwide and further a large number of biotech products are in pipeline.
Advances in biotechnology over the past 20 years have allowed pharmaceutical
companies to produce safer, cheaper enzymes with enhanced potency and specificity.
One such kind of drugs includes r-Streptokinase, r-Follicle stimulating hormone,
r-Somatropin were taken up for evaluation at enzymes and hormones laboratory.
Guidance Manual-Quality control testing of Streptokinase Page 9 of 42
NIB/EHL/GM/01
1.1. Introduction to Streptokinase:
Streptokinase is a 47-kDa (414-amino-acid) protein from pathogenic strains of the
Streptococcus. To dissolve a blood clot, streptokinase forms a 1:1 molar complex with
plasminogen, by converting plasminogen to plasmin with a half-life of 30 min.
The extracellular enzyme streptokinase is produced by various strains of h-hemolytic
streptococci. The enzyme is a single-chain polypeptide that exerts its fibrinolytic action
indirectly by activating the circulatory plasminogen. The complete amino acid sequence of
streptokinase was first established by Jackson and Tang. The protein exhibits its
maximum activity at a pH of approximately 7.5 and its isoelectric pH is 4.7 .The protein
does not contain cystine, cysteine, phosphorous, conjugated carbohydrates and lipids.
Streptokinase produced by different groups of streptococci bacteria, differ considerably in
their structure. Consequently, research has focused on structurally modifying
streptokinase to extend half-life, reduce or eliminate immunogenicity, and improve
plasminogen activation. Structurally modified streptokinases have been produced in
several ways including genetic mutation, recombinant DNA technology and chemical or
enzymatic modification of the native streptokinase.
Mutant streptokinases with improved stability have been prepared. Two of the major sites
of the proteolytic action of plasmin on streptokinase are Lys59 and Lys386. This
knowledge has been used to engineer variants of streptokinase that are resistant to
plasmin and, therefore, have a longer functional half-life. The plasmin-resistant forms of
streptokinase have been found to be as active as the native streptokinase. Recombinant
streptokinase also produced in other vectors like yeast Pichia pastoris is glycosylated, and
this appears to enhance its resistance to proteolysis.
Following a similar path, attempts have been made to extend the half-life of native non-
glycosylated streptokinase by complexing it with polymers such as polyethylene glycol
(PEG). Plasmin-resistant, long-life variants of protein-engineered streptokinase have been
Guidance Manual-Quality control testing of Streptokinase Page 10 of 42
NIB/EHL/GM/01
produced in a protease-deficient recombinant Bacillus subtilis WB600. It appears that the
streptokinase domains responsible for activity, stability and immunogenicity have
considerable overlap. Therefore, a future therapeutically optimal streptokinase will not be
necessarily the most active nor the longest lived.
Streptokinase variants with one or more of the normal amino acids residues replaced by
others have been prepared in attempts to enhance plasminogen activation. Some of the
modified variants displayed an enhanced stability. The preferred variant had Lys59
replaced with a glutamic acid residue. Streptokinase derivatives having platelet
glycoprotein-binding domains have been reported. These derivatives produced higher
local concentrations of plasmin in vivo when compared to unmodified streptokinase.
Commercial production of streptokinase requires special attention to biosafety
considerations because the protein is potentially immunogenic to process workers.
In addition, care is necessary if streptokinase is being produced using natural strains of
streptococci because all streptokinase producing streptococci are potentially pathogenic.
Streptokinase is immunogenic and can cause drug resistance, fever, and allergic
reactions. Streptokinase is certainly more cost-effective; however, its use is not risk free.
Streptokinase mechanism
Guidance Manual-Quality control testing of Streptokinase Page 11 of 42
NIB/EHL/GM/01
Natural Streptokinase amino acid sequence
Chemical
Formula C2100H3278N566O669S4
Chemical
Structure
Streptokinase
IAGPEWLLDRPSVNNSQLVVSVAGTVEGTNQDISLKFFEIDLTSRPAHGGKTEQGLSPKS
KPFATDSGAMSHKLEKADLLKAIQEQLIANVHSNDDYFEVIDFASDATITDRNGKVYFAD
KDGSVTLPTQPVQEFLLSGHVRVRPYKEKPIQNQAKSVDVEYTVQFTPLNPDDDFRPGLK
DTKLLKTLAIGDTITSQELLAQAQSILNKNHPGYTIYERDSSIVTHDNDIFRTILPMDQE
FTYRVKNREQAYRINKKSGLNEEINNTDLISEKYYVLKKGEKPYDPFDRSHLKLFTIKYV
DVDTNELLKSEQLLTASERNLDFRDLYDPRDKAKLLYNNLDAFGIMDYTLTGKVEDNHDD
TNRIITVYMGKRPEGENASYHLAYDKDRYTEEEREVYSYLRYTGTPIPDNPNDK
1.2. Quality control testing procedures:
Sample receiving procedures:
Lab Personnel receives the coded samples along with the Sample receiving register and
entries done by Sample receiving unit are verified by the analyst and acknowledged.
Physical verification of the code of sample on all the vials/bott les, total number of
vials/bottles received with cold chain and entered in to the lab register with an individual
identification number of the lab to be given to each batch by the analyst, submitted to the
laboratory head for information and signatures. In case of non receipt of samples,
mentioning specific reason for not receiving the samples in the register and acknowledged.
Table: 1.1
S.No SRRDU Code No.
Assigned Lab ID No.
Name of the product and dose/ Strength
No. of vials received for
testing
Guidance Manual-Quality control testing of Streptokinase Page 12 of 42
NIB/EHL/GM/01
Sample receiving, transfer and testing plan
Verifying the vials received for QC testing were then allocated as per testing plan at
Enzymes and Hormones Laboratory to conduct specific test parameter as T1, T2…as
follows. The tests which are performed by central facility and other testing laboratories,
were segregated and sumitted to concern laboratory along with particular proforma for inter
laboratory testing.
PROFORMA FOR INTER LABORATORY SAMPLE TRANSFER
Ref. No: Date:
Test to be conducted for:
Method to be followed:
SAMPLE DETAILS:
S. No SRRDU Code No.
Lab ID No.
Name of the product No. of vials submitted
Status of vials on receipt Cold chain maintained YES / NO
Seal intact YES / NO
Remarks:
Received by Name & signature with date.
…………………………. …………………….
Signature of Lab Head/ I/c Signature of Lab Head
E&H Laboratory
Guidance Manual-Quality control testing of Streptokinase Page 13 of 42
NIB/EHL/GM/01
Data compilation and Preparation of Certificate of Analysis:
After completing preliminary tests, compilation of data, analyzed and a Certificate of
Analysis (CoA) for decoding the sample is prepared and submitted to SRRDU alongwith
with the raw data and formats. The SRRDU decodes the sample and submits all the
documents received from the manufacturer / importer to the laboratory. Up on receiving the
documents, the laboratory scrutinize the documents and comments on summary of
protocol is prepared. The analyst prepares final Certificate of Analysis and the file is
submitted to the Director for approal before relaese of test report.
Table. 1.2.
S.No Documents required Submitted by
manufacturer / Importer
Yes/No
Comments Remarks
1. Certificate of analysis of the
finished product with name of pharmacopoeia complied
2. Letter of DCG(I)/ADC/ Port office/CDSCO
/Manufacturer‟s Letter
3. Manufacturing protocol
4. Batch Release Certificate from NCL/Manufacturer of country of
Origin
5. Copy of test/ import / manufacturing license
6. Non-withdrawal certi ficate
7. Product insert
Guidance Manual-Quality control testing of Streptokinase Page 14 of 42
NIB/EHL/GM/01
Test parameters conducted on Streptokinase for evaluation as follows.
Streptokinase bulk:
Table: 1.3.
S.No Test Parameter Specification Pharmacopoeia followed
1. Description Complies with the monograph Streptokinase IP2010.
2. Identification Method: A Clot forms and lyses with in 30mins in with citrated human plasma and lyses does not occur with in 1 hour with citrated bovine plasma.
IP2010.
3. pH 6.8 to 7.5 in 5000 IU/ml
IP2010.
4. Loss on drying Not more than 4.0% on 1g by drying over Phosphorus pentoxide at a pressure not exceeding 2.7 kPa for 24 hours.
IP2010.
5. Streptodornase activity Not more than10 IU of Streptodornase activity/ 1, 50,000 IU of Streptokinase activity per ml. (A3+A4)-(A1+A2)< (A5+A6+A7+A8) / 2- (A3+A4) at 260 nm
IP2010.
6. Streptolysin activity Not more than 1.5 times absorbance obtained by the reference standard at 550 nm.
IP2010.
7. Assay The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The confidence limits (P = 0.95) of the estimated potency are not less than 80 per cent and not more than 125 per cent of the stated potency.
IP2010.
8. Bacterial endotoxin NMT 0.02 EU/ 100 IU of Streptokinase activity. Complies with test for BET.
IP2010.
9. Abnormal toxicity Complies with test for Abnormal toxicity IP2010.
10. Sterility Complies with test for sterility IP2010.
Guidance Manual-Quality control testing of Streptokinase Page 15 of 42
NIB/EHL/GM/01
Test parameters of Streptokinase injection:
Table: 1.4.
S.No Test parameter Specification Pharmacopoeia followed
1. Clarity Clear, no visible residues found on visual observation IP 2010
2. Particulate matter Free from particles on visual inspection IP 2010
3. Identification Method: A Clot forms and lyses occurs with in 30mins in with citrated human plasma and lyses does not occur up to 1 hour with citrated bovine plasma.
IP 2010
4. pH 6.8 to 7.5 in 5000 IU/ml
IP 2010
5. Streptodornase Activity A1-A2< 0.5 (A3+A4) - A2 at 260 nm IP 2010
6. Streptolysin Activity Not more than 1.5 times absorbance obtained by the reference standard at 550 nm.
IP 2010
7. Assay The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The confidence limits (P = 0.95) of the estimated potency are not less than 80 per cent and not more than 125 per cent of the stated potency.
IP 2010
8. Bacterial Endotoxin NMT 23.33 EU/ 10000 IU of Streptokinase per ml. Complies with test for BET
IP 2010
9. Sterility Complies with test for sterility IP 2010
Guidance Manual-Quality control testing of Streptokinase Page 16 of 42
NIB/EHL/GM/01
Test parameters of r-Streptokinase injection:
Table: 1.5.
1.3. Infrastructure:
The laboratory is equipped with instruments like High Performance Liquid
Chromatography (HPLC), UV-Visible spectrophotometer, Micro plate Reader, Micro plate
washer, Vertical Electrophoresis System, pH meter, Kjeldahl apparatus, Vacuum Oven,
Refrigerated centrifuge, Digital Water bath with external temperature recorder, Incubator,
Under Counter Freezer, Electronic Weighing Balance and other basic facilities like, Bio-
safety cabinets, Fume hood etc. Major equipment are placed under annual maintenance
contract (AMC) and calibrated annually by an NABL accredited laboratory or equipment
specific vendors as per preventive maintenance schedule.
Intermediate Performance checks: To give an accurate and reproducible result the
intermediate checks for equipment is performed by the lab personnel as per the schedule
according to the concern equipment SOP. Any deviation from acceptance criteria of
equipment during the check is intimated to the vendor for rectification.
S.No Test parameter Specification Pharmacopoeia followed
1. Clarity Clear, no visible residues found on visual observation IP 2010
2. Particulate matter Free from particles on visual inspection IP 2010
3. Identification Method: A Clot forms and lyses occurs with in 30mins in with citrated human plasma and lyses does not occur up to 1 hour with citrated bovine plasma.
IP 2010
4. pH 6.8 to 7.5 in 5000 IU/ml
IP 2010
5. Assay The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The confidence limits (P = 0.95) of the estimated potency are not less than 80 per cent and not more than 125 per cent of the stated potency.
IP 2010
6. Bacterial Endotoxin NMT 23.33 EU/ 10000 IU of Streptokinase per ml. Complies with test for BET
IP 2010
7. Sterility Complies with test for sterility IP 2010
Guidance Manual-Quality control testing of Streptokinase Page 17 of 42
NIB/EHL/GM/01
List of equipment in Enzymes and Hormones Lab:
Table: 1.6.
S. No Name of the Equipment S. No Name of the Equipment
1. U.V/Visible
Spectrophotometer
8 pH meter
2 Electronic Balance 9 Refrigerated Centrifuge
3 Microplate Reader 10 Water bath (Digital)
4 Micro centrifuge 11 Bio Safety cabinet
5 Refrigerator 20 To 80C 12 Fume hood
6 BOD Incubator 13 Vortex mixer
7 Hot air oven 14 Microplate washer
1.4. Chemicals, reagents and labware
An indenting process involves identification of suitable/ probable vendors along with
the track record of items supplied for its quality, timeliness and satisfactory remarks. With
all these information the chemicals, reagents and labware were purchased based on
vendor evaluation. This will then undergo technical suitability and appropriate quantity
requirement and justification in the indent and proceed to the process of procurement as
per the policy.
1.5. Reference standards
The laboratory maintains repository of various International Reference Standards with
metrological traceability. These are procured from National Institute of Biologicals Standard
and Control (NIBSC) U.K., and stored in the Central Reference Standards Laboratory at
-860C. These standards are used for estimation of potency assays and other test
parameters (Streptodornase activity and Streptolysin activity in case of Streptokinase) as
per the requirement for the evaluation of samples.
Guidance Manual-Quality control testing of Streptokinase Page 18 of 42
NIB/EHL/GM/01
List of Reference standards available
Table: 1.7.
Reconstitution of reference standards to prepare working reference preparation:
(Streptokinase reference standard 1030 IU/Amp)
All the activities related to reconstitution, aliquoting should be performed in
biosafety cabinet. Allow the lyophilized ampoule to attain room temperature , tap the
ampoule gently to collect the material to the bottom. Take care that no material is lost from
the ampoule and no glass should falls into the ampoule. Add 1030 µl of Water for injection
to vial containing the reference material to give 1000 IU/ml working standard and vortex
gently.
Aliquoting of reconstituted Streptokinase reference preparation:
Take out 15 µl from reconstituted working reference preparation (1000 IU/ml)
ampoule to 0.5 ml microcentrifuge tubes and capped tightly. The microcentrifuge tubes
are numbered as follows (Eg.STK/Ref/1/60,STK/Ref/2/60etc.,) and store the entire vials in
–860C deep freezer. These vials were used in the test and prepared as per the dilution. Fill
the details of vials in Reference standard stock register and fi le. The micropipette tips and
ampoules are discarded as per biosafety procedures.
S. No Name of the Standard Catalogue No. Source
1. Streptokinase 00/464 NIBSC, U.K.
2. Streptokinase and Streptodornase 62/007 NIBSC, U.K.
3. Anti-Streptolysin-O 97/6620 NIBSC, U.K.
Guidance Manual-Quality control testing of Streptokinase Page 19 of 42
NIB/EHL/GM/01
Transport and use of working reference preparation:
Take out the reference material from the -860C ultra freezer for use and keep it in a
temperature controlled container / mini-cooler. The reference material is used as soon as
possible by diluting with tris buffer solution.
Preparation of Working Reference preparation:
Take one micro-centrifuge vial (eg.STK/Ref/1/60), pipette out 10 µl of 1000 IU/ ml and
add to vial containing 990 µl of Tris buffer to give 10 IU/ml. Table for dilution of working
reference standard for potency testing of Streptokinase as follows.
Table: 1.8.
S. No IU/ml Volume of 10/ml Volume of Buffer Total volume
1 0.5 IU/ml 50 µl 950 µl 1000
2 1.0 IU/ml 100µl 900µl 1000
3 2.0 IU/ml 200µl 800µl 1000
4 4.0 IU/ml 400 µl 600µl 1000
Guidance Manual-Quality control testing of Streptokinase Page 20 of 42
NIB/EHL/GM/01
NIBSC 3rd INTERNATIONAL REFERENCE STANDARD
STREPTOKINASE (1030 IU).
Catalogue No: 00/464
Aliquoted on : ________________
Description: Added 1030 µl of WFI and Dispensed 15 µl to each vial, designated as STK
from 1/60 to 60/60, Store at -860C, make an entry with date at the box
provided against the use.
Scheme of vials used:
1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
11. 12. 13. 14. 15. 16. 17. 18. 19. 20.
21. 22. 23. 24. 25. 26. 27. 28. 29. 30.
31. 32. 33. 34. 35. 36. 37. 38. 39. 40.
41. 42. 43. 44. 45. 46. 47. 48. 49. 50.
51. 52. 53. 54. 55. 56. 57. 58. 59. 60.
Remarks:
Guidance Manual-Quality control testing of Streptokinase Page 21 of 42
NIB/EHL/GM/01
1.6. Central facility laboratories (Inter laboratory testing)
The test parameters conducted at central facility laboratories includes abnormal
toxicity and Sterility. The samples are forwarded to testing lab along with inter-laboratory
testing format with duly signed by the laboratory head indicating the tests to be performed
on samples along with the product insert.
Animal related tests were conducted in animal facility with the pre-approval of
protocols by the Institutional Animal Ethics Committee (IAEC), test procedures were
carried up on animals as per regulatory guidelines.
Sterility test is conducted as per the method recommended by the monograph.
1.7. QC test parameters conducted at EHL:
Bio-physico-chemical properties and safety of biotherapeutics are tested /conducted
as per the monographs of Indian Pharmacopoeia method followed by the manufacturer or
any other Pharmacopoeia followed. Written SOPs should be followed to conduct the test
parameters, equipment use and documentation. Bench protocols, formats for test results,
and statistical software for calculating potency of Streptokinase for evaluation are followed
as per ISO/ IEC 17025 guidelines.
1.8. Bio-safety procedures to be followed in laboratory for safe disposal of
biomedical waste:
Bio-safety, a key component of total quality control programme. There is a potential risk
of infection to the laboratory staff who handle samples of body fluids/tissues, infected
waste and infected specimens etc..
Guidance Manual-Quality control testing of Streptokinase Page 22 of 42
NIB/EHL/GM/01
There are several ways that workers can acquire blood borne infection from a donor or
from his/her specimen either by:
1. Direct contact with blood / body fluids
2. Accidental inoculation of infected blood/body fluids
3. Accidental cuts with contaminated sharps
4. Indirect contact with contaminated equipment or any other inanimate infected
object.
In a laboratory, all bio-safety measures should be ensured and workers must take all
precautionary measures to protect themselves from accidental injury while handling the
blood.
Bio-safety procedures
1. All laboratory staff shall be vaccinated against Hepatitis B and immunization
records be maintained.
2. Only authorized persons enter the laboratory working areas.
3. Keep laboratory doors closed.
4. Keep children out of laboratory areas.
5. Do not wear open toed footwear /street shoes in laboratories- change footwear
before entering /leaving.
6. Wear protective clothing when working in the laboratory and remove before leaving
the laboratory.
7. Store used protective laboratory clothing in separate lockers or cupboards.
8. Eating, drinking, smoking, applying cosmetics and handling contact lenses is
prohibited in the laboratory.
9. Storing foods or drinks for consumption anywhere in the laboratory areas is
prohibited.
10. Wear protective gloves and personnel should disinfect their hands before and after
using gloves.
11. Gloves must be removed and discarded after completion of bench work.
Guidance Manual-Quality control testing of Streptokinase Page 23 of 42
NIB/EHL/GM/01
Decontamination:
Work bench practices
I) Used microtips are discarded in 1% sodium hypochlorite solution.
II) Test devices are discarded in 1.0% Sodium Hypochlorite solution after the test .
III) Reagents/ controls from kits (Positive Control, Negative Control) are emptied into
1% Sodium Hypochlorite and discarded directly into zip lock bags.
IV) Used gloves, filter paper sheets spread on workbench and alcohol / Hypo swabs
are also discarded into a punched zip lock bags.
V) The collected waste is allowed to stand for overnight in contact with 1% Hypo and
emptied into punched zip lock bag.
VI) The punched zip lock bags containing all kinds of wastes are collected into larger
punched biohazard bags.
VII) Two or three such bags are placed in the decontamination autoclave and
autoclaved at 1210C , 15 psi for 40 minutes.
viii) All instrument touch points, single channel pipettes, marker pens, forceps,
refrigerator are swabbed with 70% alcohol after use.
1.9. Description of test parameters applicable for Streptokinase bulk, injection
Identification by Clot lyses method:
Procedure: Place 0.5 ml of citrated human plasma in a hemolysis tube maintained in a
water-bath at 37°C. Add 0.1 ml of a dilution of the preparation under examination
containing 10 000 IU of streptokinase activity per milliliter in phosphate buffer pH 7.2 and
0.1 ml of a solution of human thrombin containing 20 IU/ml in phosphate buffer pH 7.2. Mix
immediately.
Acceptance criteria: A clot forms and lyses within 30 min in tube containing Streptokinase
and citrated human plasma. Repeat the procedure using citrated bovine plasma. The clot
does not lyse within 60 minutes.
Results proforma: See annexure-I
Reference: Indian Pharmacopoeia 2010.
Guidance Manual-Quality control testing of Streptokinase Page 24 of 42
NIB/EHL/GM/01
pH Determination:
Procedure: Determine the pH of solution prepared by diluting the streptokinase in water
for injection to obtain a solution containing 5000 IU of streptokinase activity per milli liter.
Acceptance criteria: 6.8 to 7.5
Reference: Indian Pharmacopoeia 2010.
Test for pH
EQUIPMENT DETAILS:
pH meter:
Equipment ID:
Calibrated on:
Details of Reference buffer(s) used in calibration
Product name/Sample code:
Manufacturer:
Batch No: Mfg. date: Exp. date:
Reference Buffer Source Date of Expiry Readings
4.01
7.0
9.0
Name of product/
sample code
Reading-1 Reading-2 Reading-3 Average Comply/ Not
comply
Guidance Manual-Quality control testing of Streptokinase Page 25 of 42
NIB/EHL/GM/01
Results:
Streptodornase activity:
Reconstitution of Streptokinase – International Reference Standard for Streptodornase
(2400 IU) & Streptokinase 3100 IU – NIBSC (62/007) – Add 1 ml of water for injection to
the ampoule containing Streptokinase (3100 IU) and Streptodornase (2400 IU) and vortex.
Aliquoted 10 µl of reconstituted reference preparation into sterile microcentrifuge tubes
(1.5ml), designated as STDR (Streptodornase), numbered accordingly (1/STDR,
2/STDR…,) & immediately stored at -860C.
Preparation of working preference reparation of Streptodornase:
Take out one microcentrifuge tube of 1.5ml containing 10 µl of aliquot, add 1190 µl of
Imidazole buffer pH 6.5 to achieve streptodornase activity of 20 IU/ml, i.e. (120 time‟s
dilution).
Procedure:
Add 0.5 ml of a 0.1 % w/v solution of sodium deoxyribonucleate in imidazole buffer pH
6.5 into each of eight centrifuge tubes. In each of the first two tubes add 0.25ml of
imidazole buffer of pH 6.5 and 0.25ml of solution of the Streptokinase (150,000 IU / ml) in
imidazole buffer pH 6.5 followed immediately by 3.0 ml of 0.25M Perchloric acid. Mix the
contents of each tube. Centrifuge for 5 minutes at 3000 rpm and measure the absorbance
of the each of the supernatant liquids at about 260 nm using as the blank a mixture of 1.0
ml of imidazole buffer pH 6.5 and 3.0 ml of 0.25M perchloric acid. Calculate two
absorbencies as A1 and A2 respectively for first and second tubes. In each of the
remaining six tubes (numbered as 3 to 8) add, respectively 0.25, 0.25, 0.125, 0.125, 0 and
0 ml of imidazole buffer pH 6.5 followed by 0.25 ml solution of the Streptokinase (150,000
IU / ml) and finally 0, 0, 0.125, 0.125, 0.25 and 0.25 ml respectively of a solution of the
working Standard Preparation containing 20 Units of Streptodornase activity/ ml in
imidazole buffer pH 6.5. Mix the contents of each tube, incubate at 37o C for 15 minutes
and add to each tube 3.0 ml of 0.25M Perchloric acid. Mix the contents of each tube,
Guidance Manual-Quality control testing of Streptokinase Page 26 of 42
NIB/EHL/GM/01
centrifuge and measure the absorbencies as A3 to A8 of each of the supernatant liquids at
260 nm, using as the blank the mixture specified above. Calculation is performed by using
the formula: (A3+A4)-(A1+A2) < (A5+A6+A7+A8) / 2- (A3+A4).
Limit: Not more than 10 IU of Streptodornase activity per 100 000 IU of streptokinase
activity for streptokinase bulk.
Acceptance criteria: (A3+A4)-(A1+A2) < (A5+A6+A7+A8)/2- (A3+A4) for Streptokinase
Bulk solution and (A1 -A2) is less than 0.5 (A3+A4)-A2 for Streptokinase injection and
Streptokinase as per IP 2010.
Results proforma: See annexure-II
Reference: Indian Pharmacopoeia 2010.
Streptolysin activity:
Preparation of working reference of Anti-Streptolysin-O, Human- NIBSC Reagent 97/662:
Add 50 µl of 10 IU/ml Anti Streptolysin-O, Human reference reagent to tube containing 50
µl of buffer (9 volumes of 0.9% saline and Citrophosphate buffer of pH 7.2) to prepare 5
IU/ml working reference reagent.
Preparation of 1.6% Rabbit erythrocyte Suspension:
Collect 5ml of blood in 3.2% w/v EDTA from Rabbit.
Centrifuge at 2000 rpm for 10min and discard the plasma
Take 0.5 ml settled erythrocyte and make up to 25ml with 0.9% saline solution, in centrifuge tube
Centrifuge at 3000 rpm for 20 minutes and after centrifugation discard the supernatant
Wash four times until a clear supernatant
Dilute 0.8ml of the suspension of erythrocytes to 50ml (1.6 %) with a mixture of
1 volume of citrophosphate buffer pH 7.2 & 9 volumes of a 0.9% w/v solution of sodium chloride.
Prepared suspension may be used up to one month, stored at 20 to 80 C:
Guidance Manual-Quality control testing of Streptokinase Page 27 of 42
NIB/EHL/GM/01
Procedure:
Take Streptokinase bulk in 500,000 Units in 0.5 ml in a mixture of 90 volumes of
saline solution and 10 volumes of Citrophosphate buffer pH 7.2 in a sterile glass tube. Add
0.4 ml of a 2.3% w/v solution of sodium thioglycollate and incubate in water bath at 37oC
for 10 minutes.
Add 0.1 ml of a solution of a reference reagent of human Antistreptolysin-O (5
IU/ml) for each tube and incubate at 37oC for 5 minutes. Add 1.0 ml of rabbit erythrocyte
suspension; continue the incubation for 30 minutes and centrifuge at about 1000 rpm.
Repeat the above procedure using 0.5 ml blank (mixture of saline solution and
Citrophosphate buffer pH 7.2) in place of Streptokinase solution. Measure the absorbance
of the supernatant of the test and blank at 550 nm.
Acceptance criteria: The absorbance of the test solution is not more than 50 per cent than
that of the reference solution.
Results Proforma: See annexure-III
Reference: Indian Pharmacopoeia 2010.
Loss on drying:
Procedure: Determine on 1g by drying over Phosphorus pentoxide at a pressure not
exceeding 2.7 kPa for 24 hour
Acceptance criteria: Not more than 4.0%
Reference: Indian Pharmacopoeia 2010.
Guidance Manual-Quality control testing of Streptokinase Page 28 of 42
NIB/EHL/GM/01
Assay/Potency by Chromogenic method:
Procedure: The potency of streptokinase is determined by comparing its capacity to
activate plasminogen to form plasmin with the same capacity of a reference preparation of
streptokinase calibrated in International Units; the formation of plasmin is determined using
a suitable chromogenic substrate.
The International Unit is the activity of a stated amount of the International Standard
for streptokinase. The equivalence in International Units of the International Standard is
stated by the regulatory authority.
Reference and test solutions: Prepare two independent series of four dilutions of
each of the Streptokinase sample and of the reference preparation of streptokinase in
tris(hydroxymethyl) aminomethane sodium chloride buffer pH 7.4 , in the range of 0.5, 1.0,
2.0 and 4.0 IU/ml. Prepare and maintain all solutions at 37 °C.
Substrate solution: Mix 1.0 ml of tris (hydroxymethyl) aminomethane buffer pH 7.4
with 1.0 ml of chromophore substrate.
Add 5 µl of a 10 % w/v of Polysorbate /Tween 20, Keep at 37 °C in a water-bath.
Immediately before commencing the activation assay, add 45 µl of a 1 mg/ml solution of
human plasminogen. Analyse each streptokinase dilution, maintained at 37 °C, in
duplicate. Initiate the activation reaction by adding 60 µl of each dilution to 40 µl of
substrate solution. For blank wells, use 60 µl of tris (hydroxymethyl) aminomethane
sodium chloride buffer solution pH 7.4 instead of the reference and test solutions. Allow
the reaction to proceed at 37 °C for 20 min in a water bath and read the absorbance at 405
nm.
Add 50 µl of a 50 per cent V/V solution of glacial acetic acid. Best results are
obtained when the absorbance for the highest streptokinase concentration is between 0.1
and 0.2 (after blank subtraction). If necessary, adjust the time of incubation in order to
reach this range of absorbances.
Guidance Manual-Quality control testing of Streptokinase Page 29 of 42
NIB/EHL/GM/01
Streptokinase bulk solution intend for use in the manufacture of parenteral
preparations without a further appropriate procedure for the removal of Bacterial
endotoxins complies with the following additional requirement.
Acceptance criteria: The estimated potency is not less than 90 per cent and not more
than 111 per cent of the stated potency. The confidence limits (P = 0.95) of the estimated
potency are not less than 80 per cent and not more than 125 per cent of the s tated
potency.
Calculations by Statistical analysis: Calculate the regression of the absorbance on log
concentrations of the solutions of the substance under examination and of the reference
preparation of streptokinase and calculate the potency of the substance under examination
using the usual statistical methods for parallel-line assays.
Results proforma: See annexure-IV
Reference: Indian Pharmacopoeia 2010.
Bacterial endotoxin test by Gel clot method:
This method explains to conduct bacterial endotoxin detection by gel clot method using
LAL test kit.
Method: This method is followed to perform Bacterial endotoxin limit test using Limulus
Amoebocyte Lysate (LAL) kit by gel clot method for Streptokinase injection.
Preparation of LAL, CSE and Sample dilution to MVD:
Depyrogenation: All materials coming in contact with the specimen or test reagents must
be endotoxin free. Perform the test carefully to avoid contamination &depyrogenate all
glassware at 250 °C for 30minutes.
Preparation of LAL Reagent (Lysate): A lyophilized vial of LAL reagent is reconstituted
with LAL Reagent water (LRW) as per the certificate of analysis and do not vortex.
Guidance Manual-Quality control testing of Streptokinase Page 30 of 42
NIB/EHL/GM/01
Preparation of Control standard Endotoxin (CSE):
Reconstitute the vial of CSE with 5ml of LAL reagent water (LRW) or as indicated
in the Certificate of Analysis (CoA) supplied by the manufacturer to get 40 EU/ml, vortex
vigorously for 5 minutes before use. Prepared the dilutions 2λ, 1λ, 1/2λ, 1/4 λ as per the
chart with 0.5 EU/ml or 4λas working endotoxin solution.
CSE Calculations must be done as per manufacturer‟s CoA.
(Example given below)
Control Standard Endotoxin 200EU/Vial (Lyophilized)
Add 5 ml of LRW =50EU/ml (CSE)
Preparation of working control standard Endotoxin (CSE):
Take 100 µl of 50 EU/ml CSE + 900 µl of LRW (Tube 1)= 5 EU/ml
Take 100 µl of above solution (from tube 1) + 900 µl of LRW (Tube 2)= 0.5 EU/ml i.e. 4λ
The CSE 0.5 EU/ml is used to prepare serial dilutions in (Duplicates).
i.e.,0.25EU/ml, 0.125EU/ml, 0.06EU/ml & 0.03EU/ml as shown in the below table.(These
dilutions are made in 16 x 100 mm Endotoxin free or Depyrogenated glass tubes)
Table. 1.9.
S.No CSE
(volume μL)
LRW
(in μL)
Final CSE con. (EU/ml)
1. 125 µl of 0.5 EU/ml 125 µl 0.25(2 λ)
2. 125 µl of 0.25 EU/ml 125 µl 0.125(1λ)
3. 125 µl of 0.125 EU/ml 125 µl 0.06(1/2 λ)
4. 125 µl of 0.06 EU/ml 125 µl 0.03(1/4 λ)
Guidance Manual-Quality control testing of Streptokinase Page 31 of 42
NIB/EHL/GM/01
Preparation of working solution (sample) from Streptokinase Injection 15 Lakhs/ vial to
10,000 IU/ml for Maximum valid dilution (MVD) as follows:
Preparation of Streptokinase 15, 00,000 IU/Vial dilution to 10,000 IU/ml:
Streptokinase 15, 00,000 IU/Vial
Reconstitute with 5 ml LRW (3, 00,000 IU / ml)
100μL of 3, 00,000 IU/ml (30,000 IU/ ml) +900μL LRW
(1:10) (VORTEX)
300μL of 30,000 IU/ml +600μL LRW
(1:2) (VORTEX)
Streptokinase 10,000 IU/ ml:
(Used to calculate the MVD for BET)
Maximum valid dilution is calculated based on the three values
i. Allowable limit (23.33 EU/10000 per ml of Streptokinase activity)
ii. Sample Concentration (10,000 IU/ml)
iii. Declared sensitivity of the lysate (λ) used in the test.
Based on the above values the MVD is calculations were carried out and the number of
times to be diluted the sample is arrived.
Determination of Maximum valid dilution (MVD) for Streptokinase:
The Maximum Valid Dilution (MVD) is the maximum allowable dilution of a sample at
which the endotoxin limit can be determined using the following formula:
MVD= Endotoxin limit (EU/mg or EU/Unit)x Potency/Concentration of test solution
λ (Labeled Sensitivity) (EU/ml)
Guidance Manual-Quality control testing of Streptokinase Page 32 of 42
NIB/EHL/GM/01
23.33 EU/ml x 10,000 IU/ml
= 0.125 EU/ml
= 187 times to be diluted the Streptokinase 10,000 IU/ml.
MVD= 186 times (Rounded off)
Since adapting 50:50 method the sample dilution must be MVD/2.
MVD = 186 times = 93 times
2 2
Dilution of sample to 90 times:
100 µl 10,000 IU/ml Streptokinase + 930 µl of LRW (Tube 1) = 10 times
100 µl of the above solution + 800 µl of LRW (Tube 2) = 9 times dilution
(Used to conduct the MVD for BET)
Dilutions of CSE, Test, PWC, NWC, PPC & Lysate:
(These dilutions are made in 10 x 75 mm Endotoxin free or Depyrogenated glass tubes)
Table No.1.10.
S.No Lysate Sensitivity
(λ)
LRW (volume μL)
CSE (volume μL)
Test Sample of MVD/2 dilution
(volume μL)
LAL Reagent (volume μL)
1. 0.25 (2 λ) 50 50µl of 4 λ -- 100
2. 0.125 (1λ) 50 50µl of 2 λ -- 100
3. 0.06 (1/2 λ) 50 50µl of λ -- 100
4. 0.03 (1/4 λ)_ 50 50µl of 1/2 λ -- 100
5. PWC 50 50µl of 4 λ -- 100
6. NWC 100 -- -- 100
7. PPC -- 50 µl of 4 λ 50 100
8. NPC (Test) 50 -- 50 100
Guidance Manual-Quality control testing of Streptokinase Page 33 of 42
NIB/EHL/GM/01
Where, CSE: Control endotoxin; PWC: Positive Water Control; NWC : Negative water
control; PPC: Positive Product control, LRW: LAL Reagent Water. NPC. Negative product
control (Sample under examination).
Procedure:
(Check the determination of bacterial endotoxin Interference with the each test
sample): Place the reaction tubes (10x75mm) and designate the tubes as 2λ, 1λ, 1/2λ, 1/4
λ, PWC, NWC, PPC and test. The reagents and sample contents are pipetted in to the test
tubes as per the above table No. 10. Place the reaction tubes in 370C + 10C water bath
for 60 min (+ 2 min).
(Note: - Incubation Timing for reaction must be adhered strictly since the reaction to Lysate
to endotoxin is critical.)
The results are declared as “POSITIVE” or “NEGATIVE”,
Test acceptance criteria: A firm gel capable of maintaining its integrity when the test tube
is inverted at 1800C is considered “POSITIVE”. Absence of gel or formation of viscous
mass which does not hold when the tube is inverted is considered “NEGATIVE”.
Test validity criteria : The positive and negative water controls must exhibit their
respective identity by producing a gel clot in positive water control and a clear liquid state
(without clot) in negative control. The product positive control and test were examined to
its reactiveness and results were tabulated in the BET proforma.
Acceptance criteria for product:
Streptokinase & r-Streptokinase injection: NMT 23.33 EU/ 10000 IU of Streptokinase per ml.
Streptokinase Bulk: Less than 0.02 EU/100 IU of Streptokinase activity.
Reference: Indian Pharmacopoeia 2010.
Guidance Manual-Quality control testing of Streptokinase Page 34 of 42
NIB/EHL/GM/01
BACTERIAL ENDOTOXIN TEST BY GEL CLOT METHOD
Name of the Product:
Batch/SRDU No: Mfg.Date: Exp.Date:
Test Reagents
LAL Reagent:
LAL Test Kit Lot No.: Expiry Date:
Labelled Sensitivity:
LAL Diluent (LRW) Batch No: LAL Reconstitution Date:
Endotoxin Control:
Standard (CSE) Lot No: Expiry Date:
Labelled Potency: LAL diluent (LRW) Batch No:
CSE Reconstitution Date:
Results proforma:
Control
Series
Endotoxin Dilution (EU/ml)
0.25 (2λ) 0.125 ( λ) 0.06 (1/2λ) 0.03 (1/4 λ) End Point EU/ml
NPC (Test)
PPC
PWC
NWC
NPC (Test) = Negative Product control, PPC= Positive Product control, PWC= Positive Water Control,
NWC= Negative Water Control. Results recorded as (+ve)= Firm gel formed; (-ve)= Gel not formed
Remarks:
Guidance Manual-Quality control testing of Streptokinase Page 35 of 42
NIB/EHL/GM/01
Sterility: Complies with the test for Sterility (2.2.11) IP2010
Abnormal toxicity:
Procedure: Inject into each mouse a quantity of the preparation under examination
(diluted, if necessary, with water for injections) containing 50,000 IU of streptokinase
activity in 0.5 ml, the injection lasting 15-20 seconds.
Other parameters applicable under parenterals of powder for injection
Clarity:
Procedure: Reconstitute the injection as per manufacturer‟s instructions in leaflet. Allow to
dissolve completely. Observe for solid dissolves completely, leaving no visible residue as
undissolved matter. The constituted injection is not significantly less clear than an equal
volume of the water for injection contained in the similar container and examined in the
same manner. Compare water for injection and reconstituted sample vial for observation.
Criteria for acceptance: Clear, colourless liquid.
NIB/EHL/PRO/XV PROFORMA FOR PARTICULATE MATTER BY VISUAL OBSERVATION
Date of testing:
SAMPLE DETAILS:
S.No Name of the product/ SRRDU Code No.
Diluent volume
(ml)
Visual observation after reconstitution
Any other remarks
Tested by …………………………… Verified by……………………….
(Analyst)
Authorized by (Signature of Lab Head)
Reference: Indian Pharmacopoeia 2010.
Guidance Manual-Quality control testing of Streptokinase Page 36 of 42
NIB/EHL/GM/01
Particulate matter:
Procedure: Reconstitute the injection vial as per manufacturer‟s instructions in the leaflet.
Allow to dissolve completely. Observe for the solution is essentially free from particles of
foreign matter that can be seen on visual inspection.
Criteria for acceptance: No visual particles observed.
Results proforma:
NIB/EHL/PRO/XIV
PROFORMA FOR PARTICULATE MATTER BY VISUAL OBSERVATION
Date of testing:
SAMPLE DETAILS:
S.No Name of the product/ SRRDU Code No.
Diluent volume
(ml)
Visual observation after reconstitution
Any other remarks
Tested by …………………………… Verified by……………………….
(Analyst)
Authorized by
(Signature of Lab Head)
Reference: Indian Pharmacopoeia 2010.
Guidance Manual-Quality control testing of Streptokinase Page 37 of 42
NIB/EHL/GM/01
1.9. Documents required under scrutiny of protocols
i. Certificate of analysis of the finished product with name of pharmacopoeia complied
ii. Letter of DCG(I)/ADC/ Port office/CDSCO/Manufacturer‟s Letter
iii. Manufacturing protocol
iv. Batch Release Certificate from NCL/Manufacturer of country of Origin
v. Copy of test/ import / manufacturing license
vi. Non-withdrawal certificate
vii. Product insert
1.10. Number of vials required for batch testing/evaluation
Table.1.11
S.No Product No. of vials required for a
batch
1. Streptokinase bulk 02 Bottles
2. Streptokinase injection 10 vials
3. r-Streptokinase injection 08 Nos
1.11. Training:
Training of scientific/technical personnel is one of the mandates of NIB. Professionals from
industry, academia and government institutions/organizations, who require training on
specific products / tests /quality system may be undertaken.
Guidance Manual-Quality control testing of Streptokinase Page 38 of 42
NIB/EHL/GM/01
Annexures:
Annexure-I
IDENTIFICATION OF STREPTOKINASE BY CLOT LYSIS METHOD
Product Code/Name: Manufacturer: Batch No: Mfg Date: Exp.Date:
S.No
Plasma
(μL)
Streptokinase
In
Citrophosphate
buffer pH 7.2
(10000 IU/ml)
(μL)
Thrombin
(IU/ml)
20 IU/ml
(μL)
Time (in minutes)
3 min 5 min 10 min 15 min 20min 25 min 30 min 60min
1 Blank-500ul
2 Human
Plasma-
500ul
3 Bovine
Plasma-
500ul
Remarks:
Guidance Manual-Quality control testing of Streptokinase Page 39 of 42
NIB/EHL/GM/01
Annexure-II
STREPTODORNASE ACTIVITIY FORMAT
Sample Name: Batch No: Date of Mfg: Date of Expiry:
S.No 0.1% DNA
(ul)
Imidazole
Buffer(ul)
Test solution
(ul)
Reference 20
IU/ml(ul)Vial No.---
Perchlorate
(ul)
O.D at
260 nm
Blank -- 1000 -- --
Immediately
add
3000
Centrifuge at
3000 rpm/ 5 min Take
absorbance of
supernatant.
1 500 250 250 -- 3000
2 500 250 250 -- 3000
1+2 =A1 A1=
3 500 250 250 --
Incubate
at 370C
for 15min in
water bath
3000
4 500 250 250 -- 3000
3+4 =A2 A2=
5 500 125 250 125 3000
6 500 125 250 125 3000
5+6 =A3 A3=
7 500 -- 250 250 3000
8 500 -- 250 250 3000
7+8 =A4 A4=
Streptokinase Injection Calculations (Corrected)= (A2-A1) < 0.5 (A3+A4) -A2
Streptokinase Bulk Calculations= (A3+A4)-(A1+A2)< (A5+A6+A7+A8) / 2- (A3+A4)
Calculations:
Result:
Guidance Manual-Quality control testing of Streptokinase Page 40 of 42
NIB/EHL/GM/01
Annexure-III
ESTIMATION OF STREPTOLYSIN ACTIVITY
Code/Product name:
Manufacturer:
Batch No: Mfg.Date: Exp.Date:
Results:
Tube Streptokinase
5,00,000 Units/
0.5 ml
Buffer 2.3% w/v
Sodium
thioglycollate
Incubate
at 370c
for 10
min
5 Units of
Human
streptolysin-O
Incubate
at 370c
for
5 min
1.6 % Rabbit
Erythrocyte
suspension
Incubate
at 370c
for
30 min
Centrifuge
1000 rpm
for 10 min
Absorbance
At 550 nm
Blank1 -- 0.5 ml 400 ul 50ul of 10 IU +
50ul Buffer
1 ml
Sample
0.5 ml -- 400 ul 50ul of 10 IU +
50ul Buffer
1 ml
Sample
0.5 ml -- 400 ul 50ul of 10 IU +
50ul Buffer
1ml
Guidance Manual-Quality control testing of Streptokinase Page 41 of 42
NIB/EHL/GM/01
POTENCY ESTIMATION OF STREPTOKINSE BY CHROMOGENIC METHOD Annexure-IV
Product Name/SRRDU Code: Manufacturer: Batch No: Mfg Date:
S.No StreptokinaseIU/ml
(Final concentration)
Streptokinase*
10 IU/ml
Buffer-C
(µl)
Chromogenic Substrate(1X)
(µl)
Incubate
at 370
C for
20m
in u
p t
o a
ppear
ance o
f pale
yello
w c
olo
ur,
by k
eepin
g s
topw
atch a
dd 5
0%
GA
A w
ith
10 s
ec in
terv
al t
o e
ach tube
50% Glacial Acetate(µl)
Load into Microplate
O.D at 405nm
1 Blank 0 60 40 50
2 Ref. Std 0.5 3 57 40 50
3 Ref. Std 0.5 3 57 40 50
4 Ref. Std 1.0 6 54 40 50
5 Ref. Std 1.0 6 54 40 50
6 Ref. Std 2.0 12 48 40 50
7 Ref. Std 2.0 12 48 40 50
8 Ref. Std 4.0 24 36 40 50
9 Ref. Std 4.0 24 36 40 50
10 Sample 0.5 3 57 40 50
11 Sample 0.5 3 57 40 50
12 Sample 1.0 6 54 40 50
13 Sample 1.0 6 54 40 50
14 Sample 2.0 12 48 40 50
15 Sample 2.0 12 48 40 50
16 Sample 4.0 24 36 40 50
17 Sample 4.0 24 36 40 50
* Ref. 77Std and Sample concentration stock 10 IU/ml used to set the reaction in duplicates Details of vials used in the test:
Guidance Manual-Quality control testing of Streptokinase Page 42 of 42
NIB/EHL/GM/01
1.12. References:
i. Indian Pharmacopoeia 2010
ii. Concern SOPs of test parameters, equipment, QA/QC SOPs.
iii. Quality policy
iv. ELSEVIER Journal-Current opinion in Biotechnology 2003, 14:1-7.